Market Cap 21.76B
Revenue (ttm) 3.12B
Net Income (ttm) 1.14B
EPS (ttm) N/A
PE Ratio 16.40
Forward PE 21.85
Profit Margin 36.44%
Debt to Equity Ratio 0.00
Volume 2,654,500
Avg Vol 1,640,338
Day's Range N/A - N/A
Shares Out 642.38M
Stochastic %K 98%
Beta 0.90
Analysts Strong Sell
Price Target $37.81

Company Profile

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/...

Industry: Biotechnology
Sector: Healthcare
Phone: 45 70 20 27 28
Address:
Carl Jacobsens Vej 30, Valby, Copenhagen, Denmark
TheBehavioralTrader
TheBehavioralTrader Jan. 14 at 10:56 PM
$GMAB this swing trade alerted a few weeks ago just under $30 is working out great
0 · Reply
topstockalerts
topstockalerts Jan. 7 at 6:40 PM
Genmab announced a partnership with AI firm Anthropic to enhance its research and development operations. The collaboration will focus on building customized AI solutions powered by Claude to support Genmab’s clinical development priorities, including faster data processing, analysis, and document generation under defined controls and human oversight. Genmab said the initiative is part of its broader strategy to create a more scalable, efficient, and digitally enabled R&D engine, reducing manual workloads so teams can focus on higher-value scientific and strategic work. The partnership supports Genmab’s advancing late-stage antibody pipeline in solid tumors and hematologic malignancies, as the company continues to invest in AI and digital capabilities to accelerate patient impact. $GMAB
0 · Reply
AlxNT
AlxNT Jan. 7 at 3:27 PM
$GMAB https://ir.genmab.com/news-releases/news-release-details/genmab-partners-anthropic-accelerate-research-and-development
0 · Reply
garygb
garygb Dec. 31 at 7:06 PM
$GMAB I'm buying
0 · Reply
StocktwitsNews
StocktwitsNews Dec. 29 at 8:32 PM
Genmab Stock Slips After Discontinuing Further Development Of Cancer Drug Developed With BioNTech $GMAB $BNTX https://stocktwits.com/news/equity/markets/genmab-stock-slips-after-discontinuing-further-development-of-cancer-drug/cL7ddO5RExU
1 · Reply
notreload_ai
notreload_ai Dec. 29 at 4:26 PM
$GMAB discontinues acasunlimab development to prioritize high-impact cancer therapies including EPKINLY, petosemtamab, and Rina-S in its late-stage pipeline. https://notreload.xyz/genmab-discontinues-acasunlimab-focuses-on-key-therapies/
0 · Reply
Mergerbrief
Mergerbrief Dec. 29 at 12:58 PM
$MRUS / $GMAB – Tender Offer (Subsequent Offer Period) Expires MergerBrief.com For Full Schedule
0 · Reply
WaspofWallStreet
WaspofWallStreet Dec. 27 at 4:40 AM
$GMAB popped up on some deep scans Thinking about a 5K opening. Thoughts the good and not so good. Opinions on management etc Thanks
0 · Reply
StockConsultant
StockConsultant Dec. 23 at 2:06 PM
$GMAB Genmab stock, watch for a top of range breakout at https://stockconsultant.com/?GMAB
0 · Reply
savepig
savepig Dec. 22 at 11:34 PM
$GMAB Danish biotech: the bottom is in. BUY!
0 · Reply
Latest News on GMAB
Genmab: AI Partnership And Clinical Data Fuel Growth

Jan 10, 2026, 5:06 AM EST - 4 days ago

Genmab: AI Partnership And Clinical Data Fuel Growth


Genmab scraps development of experimental cancer therapy

Dec 29, 2025, 9:03 AM EST - 16 days ago

Genmab scraps development of experimental cancer therapy


Genmab Portfolio Prioritization Update

Dec 29, 2025, 8:12 AM EST - 16 days ago

Genmab Portfolio Prioritization Update


Genmab to Hold 2025 R&D Update and ASH Data Review Meeting

Dec 11, 2025, 2:00 AM EST - 4 weeks ago

Genmab to Hold 2025 R&D Update and ASH Data Review Meeting


Genmab A/S (GMAB) Q3 2025 Earnings Call Transcript

Nov 8, 2025, 6:46 AM EST - 2 months ago

Genmab A/S (GMAB) Q3 2025 Earnings Call Transcript


Why Is Genmab Stock Trading Lower On Monday?

Oct 20, 2025, 11:57 AM EDT - 3 months ago

Why Is Genmab Stock Trading Lower On Monday?


Genmab A/S (GMAB) M&A Call Transcript

Sep 29, 2025, 5:47 PM EDT - 3 months ago

Genmab A/S (GMAB) M&A Call Transcript


Genmab to buy Dutch cancer drugmaker Merus for $8 billion

Sep 29, 2025, 1:19 AM EDT - 3 months ago

Genmab to buy Dutch cancer drugmaker Merus for $8 billion

MRUS


Major Shareholder Announcement

Sep 23, 2025, 9:18 AM EDT - 4 months ago

Major Shareholder Announcement


Genmab: A Matter Of Time

Sep 12, 2025, 6:15 AM EDT - 4 months ago

Genmab: A Matter Of Time


TheBehavioralTrader
TheBehavioralTrader Jan. 14 at 10:56 PM
$GMAB this swing trade alerted a few weeks ago just under $30 is working out great
0 · Reply
topstockalerts
topstockalerts Jan. 7 at 6:40 PM
Genmab announced a partnership with AI firm Anthropic to enhance its research and development operations. The collaboration will focus on building customized AI solutions powered by Claude to support Genmab’s clinical development priorities, including faster data processing, analysis, and document generation under defined controls and human oversight. Genmab said the initiative is part of its broader strategy to create a more scalable, efficient, and digitally enabled R&D engine, reducing manual workloads so teams can focus on higher-value scientific and strategic work. The partnership supports Genmab’s advancing late-stage antibody pipeline in solid tumors and hematologic malignancies, as the company continues to invest in AI and digital capabilities to accelerate patient impact. $GMAB
0 · Reply
AlxNT
AlxNT Jan. 7 at 3:27 PM
$GMAB https://ir.genmab.com/news-releases/news-release-details/genmab-partners-anthropic-accelerate-research-and-development
0 · Reply
garygb
garygb Dec. 31 at 7:06 PM
$GMAB I'm buying
0 · Reply
StocktwitsNews
StocktwitsNews Dec. 29 at 8:32 PM
Genmab Stock Slips After Discontinuing Further Development Of Cancer Drug Developed With BioNTech $GMAB $BNTX https://stocktwits.com/news/equity/markets/genmab-stock-slips-after-discontinuing-further-development-of-cancer-drug/cL7ddO5RExU
1 · Reply
notreload_ai
notreload_ai Dec. 29 at 4:26 PM
$GMAB discontinues acasunlimab development to prioritize high-impact cancer therapies including EPKINLY, petosemtamab, and Rina-S in its late-stage pipeline. https://notreload.xyz/genmab-discontinues-acasunlimab-focuses-on-key-therapies/
0 · Reply
Mergerbrief
Mergerbrief Dec. 29 at 12:58 PM
$MRUS / $GMAB – Tender Offer (Subsequent Offer Period) Expires MergerBrief.com For Full Schedule
0 · Reply
WaspofWallStreet
WaspofWallStreet Dec. 27 at 4:40 AM
$GMAB popped up on some deep scans Thinking about a 5K opening. Thoughts the good and not so good. Opinions on management etc Thanks
0 · Reply
StockConsultant
StockConsultant Dec. 23 at 2:06 PM
$GMAB Genmab stock, watch for a top of range breakout at https://stockconsultant.com/?GMAB
0 · Reply
savepig
savepig Dec. 22 at 11:34 PM
$GMAB Danish biotech: the bottom is in. BUY!
0 · Reply
LeRoyRektlord
LeRoyRektlord Dec. 22 at 10:23 PM
0 · Reply
SenefAS
SenefAS Dec. 19 at 7:23 AM
Today upgrade for Genmab $GMAB $GMAB.CO of Deutsche Bank for a buy with a new target of 2400 DK… Still partnership with Pfizer,Abbvie,BioNTech $PFE $ABBV $BNTX $NVS
0 · Reply
SenefAS
SenefAS Dec. 16 at 10:28 AM
Still in Genmab… Actually my favorite one… Sciences always win 😉 $GMAB $PFE
0 · Reply
benjamin_clark07
benjamin_clark07 Dec. 11 at 8:07 PM
$GMAB Mainz Biomed letting everyone get comfy thinking it’s dead at 1.05… then one day we wake up to a gap over 1.15 and Twitter screaming “what did I miss?” 📈
0 · Reply
johankirik
johankirik Dec. 11 at 7:13 PM
$GMAB Need a strong close today to continue bullish momentum.
0 · Reply
johankirik
johankirik Dec. 11 at 7:11 PM
$GMAB surprising these guys havent been acquired yet.
0 · Reply
Mergerbrief
Mergerbrief Dec. 11 at 1:07 PM
$MRUS / $GMAB – Tender Offer Expires MergerBrief.com For Full Schedule
0 · Reply
smartkarma
smartkarma Dec. 10 at 4:21 PM
$GMAB | Genmab: How Its Combined Pipeline, Royalties & M&A Strategy Could Potentially Unlock A SOLID Upside! "The Danish biotech giant is gearing up to acquire Merus N.V., a smaller Dutch peer, in a proposed $8 billion transaction announced on September 29, 2025." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/genmab-how-its-combined-pipeline-royalties-m-a-strategy-could-potentially-unlock-a-solid-upside
0 · Reply
Hottehueh
Hottehueh Dec. 7 at 5:47 PM
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Dec. 7 at 4:36 PM
The attached graph compares $NUVB analyst consensus revenue estimates to the same for $MRUS as of the day MRUS was acquired by $GMAB for an enterprise value of roughly $7.3B. We also noted MRUS management/BOD revenue projections were 2X higher than analysts (which may be absurd for all we know). Analysts forecast NUVB to generate roughly 80% of the revenues analysts project MRUS to generate at peak. NUVB market cap is roughly 40% of MRUS's EV. NUVB also has roughly $500MM cash at 9/30/2025. This is not investment advice as NUVB may be wildly overhyped for all we know. NUVB analyst revenue projections may also be fiction. We are merely sharing comparative data points. It is quite possible NUVB loses 70-80% of its market cap over the next 6 months. If NUVB is smart & pro-shareholder, it will seek an exit while its valuation has already soared. $XBI $IBB
3 · Reply
AlertsAndNews
AlertsAndNews Dec. 6 at 9:43 PM
$GMAB GMAB Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) "New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in patients with DLBCL and FL Latest EPCORE DLBCL-3 trial results show encouraging overall response and complete response rates for epcoritamab monotherapy in newly-diagnosed, elderly patients with DLBCL"
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 3 at 10:24 AM
$GMAB Current Stock Price: $31.70 Contracts to trade: $30 GMAB Dec 19 2025 Call Entry: $1.80 Exit: $2.46 ROI: 37% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply